Global Multiple Myeloma Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Multiple myeloma is a cancer that forms in a type of white blood cell that is called a plasma cell. Plasma cells help to fight infections by making antibodies. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. For people with multiple myeloma who require treatment, a number of treatments are available to help control the disease. Scope of the Report: This report focuses on the Multiple Myeloma Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Cancer cells have higher levels of proteasome activity are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, which makes the proteasome a therapeutic target in multiple myeloma. Proteasome inhibitor treatment is preferred after there is a treatment failure with the conventional approach. The worldwide market for Multiple Myeloma Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers Amgen Johnson & Johnson Celgene Takeda Pharmaceutical Novartis Daiichi Sankyo Merck AB Science Teva PharmaMar Market Segment by Regions, regional analysis covers ...
Table of Contents 1 Market Overview 1.1 Multiple Myeloma Drugs Introduction 1.2 Market Analysis by Type 1.2.1 Immunomodulatory drugs (IMiDs) 1.2.2 Proteasome inhibitors 1.2.3 Chemotherapy 1.2.4 Histone deacetylase inhibitor (HDAC inhibitor) 1.2.5 Steroids (corticosteroids) 1.3 Market Analysis by Applications 1.3.1 Men 1.3.2 Women 1.4 Market Analysis by Regions 1.4.1 North America (United States, Canada and Mexico) 1.4.1.1 United States Market States and Outlook (2013-2023) 1.4.1.2 Canada Market States and Outlook (2013-2023) 1.4.1.3 Mexico Market States and Outlook (2013-2023) 1.4.2 Europe (Germany, France, UK, Russia and Italy) 1.4.2.1 Germany Market States and Outlook (2013-2023) 1.4.2.2 France Market States and Outlook (2013-2023) 1.4.2.3 UK Market States and Outlook (2013-2023) 1.4.2.4 Russia Market States and O ...
1934

1978

OUR CLIENT